anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Anhydrous detergent compositions, e.g. shampoos, cosmetic detergents, and glass cleaning agents, adapted to be sprayed from a pressurized aerosol container comprise (a) at least one liquefied propellant gas selected from saturated hydrocarbons containing 4 or 5 carbon atoms and chlorofluorinated derivatives of methane or ethane, and (b) a compound of formula R-(OCH2CH2)n-O-SO3NH4 wherein R is a straight hydrocarbon chain of 8-22 carbon atoms, a branched hydrocarbon chain of 10-20 carbon atoms corresponding to "oxo" alcohols, or an alkylphenyl radical, and n is 1-6.  It is preferred that R be selected from saturated straight hydrocarbon chains of 12-14 carbon atoms, unsaturated straight hydrocarbon chains of 18 carbon atoms, branched hydrocarbon chains of 11-16 carbon atoms, or octyl- or nonyl-phenyl radicals, or mixtures of such radicals.  The propellant (a) may suitably be n-butane, tri-chlorotrifluoroethane, tri-chloromonofluoromethane, or dichlorodifluoromethane, or a mixture of such compounds.  The composition which may be prepared directly (see Group IV(b)), is usually adjusted to pH 7-8 by means of ammonia gas, or by addition of anhydrous mono-, di-, or tri-ethanolamine. Urea, fatty materials, mineral oil, waxes, essences, perfumes, colorants, antiseptics and insecticides may also be incorporated.ALSO:Solutions of a compound of formula R-(OCH2CH2)nOSO3NH4 wherein R is a straight C8-22 hydrocarbon chain, a branched C10-20 hydrocarbon chain, corresponding to "oxo" alcohols, or an alkylphenyl-radical and n is 1-6 are produced directly by reacting sulphamic acid with a compound of formula R-(OCH2CH2)nOH in a solvent comprising at least one liquified propellant gas selected from saturated hydrocarbons containing 4 or 5 carbon atoms and chlorofluorinated derivatives of methane and ethane, at 110 DEG C.-130 DEG C. at a pressure equal to the vapour pressure of the solvent at that temperature, the solvent being one that does not develop a pressure above 20 atmospheres at the reaction temperature, and which dissolves the whole reaction product at ordinary temperatures.  Urea in amounts of 1%-10% by weight of the total reactants is generally added to prevent discoloration and facilitate filtration.  Residual acidity in the reaction products is neutralized and the pH adjusted to 7-8 by means of ammonia gas or mono-, di-, or tri-ethanolamine. The solutions may be used in acrosol detergent compositions (see Group III).
FIELD: organic chemistry, medicine, pharmacy. SUBSTANCE: invention proposes a new agent, pharmaceutical compositions based on said for treatment of patients with sicknesses associated with anomal stimulation of AT 1  and AT 2  receptors - the compound of the formula (I):  . Radical values are given in the invention claim. Invention proposes also new compounds showing the above indicated activity and methods of their synthesis. EFFECT: improved method of synthesis, valuable pharmacological properties. 15 cl, 87 ex
Agent for combatting hair loss (Alopecia), esp. hair loss caused by estrogen deficiency, and shifts in hormone balance, contains Royal Jelly and/or Ginseng as active agent togther with a physiologically harmless carrier, assistant, soln.  or solvating agent and opt. additional supplements e.g.  vitamins. USE/ADVANTAGE - Ginseng and Royal Jelly contain plant hormones (phytohormones) related to female estrogens, which have a positive effect on hair growth. Topical daily application to the scalp of 10 ml Royl Jelly (a substance secreted by bees) and 3 g Ginseng powder of 1 g Ginseng extract in a suitable carrier or soln. halts the hair loss, stimulates growth of new hair, and improves the quality of the hair.
Dexmedetomidine is a selective agonist of α2receptorswhose tendency to α2 receptors is eight times more than that of clonidine. It also has powerful sedative, analgesic, anti-inﬂammatory, and organ protective properties. dexmedetomidine has favorable respiratory effects in humans. The effects of dexmedetomidine on oxygenation and lung mechanics had been investigated in obstructive lung disease. Dexmedetomidine decreased dead space and improved both lung compliance and oxygenation in chronic obstructive pulmonary disease (COPD) patients undergoing lung cancer surgery. Morbidly obese patients are characterized by the high prevalence of restrictive lung disease.The study include 2 equal groups, each group is 35 patients: Group A(N=35) dexmedetomidine is infused intraoperative after intubation at dose of (1μg/Kg LBW) bolus, followed by 0.5μg/Kg/hour continuous infusion till the end of surgery and Group B(N=35) dexmedetomidine is infused intraoperative after intubation at dose of (0.5μg/Kg LBW) bolus, followed by 0.3μg/Kg/hour continuous infusion till the end of surgery.
Thyroid nodules are common and although most are benign and remain relatively static in size, some can grow and become large and cause local symptoms over time. In such scenario, thyroidectomy is usually indicated. However, surgery is not only associated with complications but also with high cost and general anesthesia. As a result, there has been a growing interest in exploring less invasive, non-surgical technique for benign thyroid nodules. For solid or predominantly-solid (\<30% cystic areas) thyroid nodules, thermal ablation techniques have been shown to be highly effective in causing nodule shrinkage and alleviating symptoms in the long-term. To date, numerous thermal ablation techniques have been described and they include radiofrequency ablation (RFA), percutaneous laser ablation (PLA), microwave ablation and more recently, high intensity focused ultrasound (HIFU). HIFU is now considered the least invasive technique as there is no need for needle insertion into the target lesion during treatment. It works by utilizing focused ultrasound energy to generate heat and induce thermal ablation beneath the skin and other tissue layers. Recent studies (including several from our group) have shown that it is effective in not only inducing significant nodule shrinkage but also in alleviating nodule-related symptoms.

However, despite its overall success, approximately 10 - 15% of solid or predominantly solid nodules do not shrink adequately (i.e. \<50% shrinkage from baseline in the first 6-12 months). Although the exact reason why some nodules do not respond remains unclear, it is noted that the majority of these less responsive nodules are larger in size / volume and so, a second or reapplication of ablation might be required to cause further shrinkage and improvement in symptoms \[11\]. However, the role of HIFU reapplication in nodules with less-than-adequate response (\<50% at 6 months) remains undefined. As a result, the present study is aimed to the feasibility and safety of HIFU reapplication in nodules with shrinkage \<50% of baseline volume 6 months after single-session HIFU treatment.
The present invention discloses a user of acidic fibroblast growth factor in preparing cosmetics, and simultaneously provides a production process. The invention uses biotechnology for beautifying. The acidic fibroblast growth factor is used for external beautifying. The physiologic status of skin is improved at root and the restoring and metabolism of epidermic tissue are promoted through complementing the biological active factors which promote the metabolism and proliferation of epidermic cell. The skin can be smoothed and young. The color spot is faded and the wrinkle is pacified. The damage of sunshine to the skin is reduced. The skin smoothing and beautifying effect is obvious. Furthermore the acidic fibroblast growth factor is safe and reliable without side effect.
N-acetyl taurine (I) is prepared by the acetylation of taurine using acetic anhydride in pure acetic acid, in the absence of water and alcohol. The stable form of (I), m.pt. 140 degrees C, which then re-solidifies and melts again at 191-192 degrees C is also claimed, as are salts of (I) with arginine, lysine and ornithine. (I) crosses the haemato-meningeal barrier more readily than taurine, and thus plays an important physiological role. Previous attempts to prepare (I) have given a product which decomposes in air. (I) prepared by this new method is stable.
Pseudomonas aeruginosa, Acinetobacter baumanii, Staph aureus and Klebsiella pneumoniae will be isolated from tracheal aspiration cultures. 80 isolates associated with pneumonia will be identified and made antibiogram with VITEK. Then antimicrobial effects of Lactobacillus bacteria (LAB) (Lc. lactis subsp. lactis (IL 1403), Lc. lactis subsp. lactis (ATCC 11454), Lactobacillus plantarum (FI8595), Leuconostoc mesenterodies subsp. cremoris (DSMZ 20346), Streptococcus thermophilus (NCFB2392), Pediococcus acidophilus (ATCC 25741)) and nisin bacteriocin will be investigated on the bacteria's growth rate in the laboratory.
The invention relates to a medicine for treating breast hyperplasia. The medicine is prepared from the following raw medicinal materials in parts by weight: 12 parts of herba violae, 8 parts of semen citri reticulatae, 9 parts of fructus trichosanthis and 6 parts of radix aucklandiae. Based on family-learned treatment experiences, an inventor comprehends the main meanings of ancient books and records in combination with pathological studies of the modern medicine on breast diseases to get summaries so as to provide the medicine for treating the breast. In the formula, the herba violae is bitter, pungent and cold in taste, belongs to the heart channel and the lung channel and has the effects of clearing way heat and toxic materials, cooling blood, relieving swelling, clearing heat and promoting diuresis; the semen citri reticulatae is bitter in taste and neutral in nature, belongs to the liver channel and the kidney channel and has the effects of regulating the flow of qi, removing stasis and relieving pain; the fructus trichosanthis has the effects of moistening dryness, dispersing stasis, dispersing heat and removing phlegm; the radix aucklandiae belongs to the liver channel and has the effects of guiding the flow of qi and relieving pain. All the medicines are combined in use for treating the breast hyperplasia, and basically the disease can be cured after the medicine is taken. Clinical experiments show that the medicine disclosed by the medicine can be safely and effectively applied to treatment on the breast hyperplasia.
A chewable calcium composition and its associated method of manufacturing are disclosed. The chewable composition includes a lipid base and a micronized calcium salt substantially uniformly mixed with the lipid base such that the lipid base forms a continuous phase. The composition provides for a relatively large dose of calcium in a easy to take chocolate like, chewable form. The composition of the present invention is manufactured by providing the lipid base including a melting temperature. The lipid base is then heated to a temperature of approximately 120° F. such that the lipid base melts. After the lipid base melts, the micronized calcium salt is mixed with the lipid base to form a melted mixture such that the micronized calcium salt is substantially uniformly distributed in the melted lipid base. Thereafter, the melted mixture may be tempered in a predetermined way before causing the mixture to solidify and then molded into chewable portions, each of which includes a predetermined amount of calcium salt. In one aspect of the invention, a predetermined portion of xylitol may be added to the melted mixture such that the xylitol is substantially uniformly distributed in the melted mixture. When the composition is consumed, the xylitol provides for salivation within the oral cavity leading to substantially rapid dissolution of the composition therein so as to provide taste and texture characteristics which are akin to those of chocolate.
Various systems generating nitric oxide are disclosed herein. According to one embodiment, the system includes a first gas source providing nitrogen dioxide mixed in air or oxygen, and a second gas source supplying compressed air and/or compressed oxygen. The system also includes a ventilator coupled to the first and second gas sources, wherein the ventilator is resistant to nitrogen dioxide. The ventilator regulates gas flow and allows for the adjustment of nitrogen dioxide concentration in the gas flow. The system further includes one or more conversion devices operably coupled to the ventilator where the conversion devices convert nitrogen dioxide into nitric oxide. A patient interface delivers nitric oxide to the patient and is operably coupled to the conversion devices. The system allows oxygen and nitric oxide levels to be varied independently.
Patients receive carboplatin IV and paclitaxel IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
A reporting system, including a processing device, and method provides drug and medical device safety and support information during a workflow of a healthcare provider. The system and method electronically acquires, maps, generates, compiles, verifies and transfers in real time critical information regarding particular drugs and medical devices required by healthcare providers, such as a prescriber, at the optimum time in which the healthcare provider needs the information. In an embodiment, the drug and medical device safety information is accessed from an associated healthcare website, such as an Electronic Health Record (EHR) web site, during a prescription stage in the healthcare providers workflow for a particular patient. The system and method also includes an adverse reporting system that allows for the drug and medical device safety information to be updated and accurately reported in an efficient and up to date manner. In an embodiment, a healthcare provider reports an adverse event or reaction to a drug by a patient during a workflow at a EHR web site. The adverse event information is forwarded to the Federal Drug Administration (FDA) and the particular drug manufacturer which may update the corresponding drug information. The updated drug information may then be reported by the system to insure that healthcare providers receive the most current, accurate and complete safety information during a workflow. In embodiments, the updated drug and medical information may be provided to malpractice insurance carriers to further ensure safety.
BACKGROUND: Although oxidative stress is involved in the pathophysiological process of chronic rhinosinusitis with nasal polyps (CRSwNP), the specific underlying mechanism is still unclear. Whether antioxidant therapy can treat CRSwNP needs further investigation.
METHODS: Immunohistochemistry, immunofluorescence, western blotting and quantitative polymerase chain reaction (qPCR) analyses were performed to detect the distribution and expression of oxidants and antioxidants in nasal polyp tissues. qPCR revealed correlations between oxidase, antioxidant enzymes and inflammatory cytokine levels in CRSwNP patients. Human nasal epithelial cells (HNEpCs) and primary macrophages were cultured to track the cellular origin of oxidative stress in nasal polyps(NPs) and to determine whether crocin can reduce cellular inflammation by increasing the cellular antioxidant capacity.
RESULTS: The expression of NOS2, NOX1, HO-1 and SOD2 was increased in nasal epithelial cells and macrophages derived from nasal polyp tissue. Oxidase levels were positively correlated with those of inflammatory cytokines (IL-5 and IL-6). Conversely, the levels of antioxidant enzymes were negatively correlated with those of IL-13 and IFN-γ. Crocin inhibited M1 and M2 macrophage polarization as well as the expression of NOS2 and NOX1 and improved the antioxidant capacity of M2 macrophages. Moreover, crocin enhanced the ability of antioxidants to reduce inflammation via the KEAP1/NRF2/HO-1 pathway in HNEpCs treated with SEB or LPS. Additionally, we observed the antioxidant and anti-inflammatory effects of crocin in nasal explants.
CONCLUSION: Oxidative stress plays an important role in the development of CRSwNP by promoting various types of inflammation. The oxidative stress of nasal polyps comes from epithelial cells and macrophages. Antioxidant therapy may be a promising strategy for treating CRSwNP.
BACKGROUND: Because of to the removal of subclassification of papillary renal cell carcinoma (pRCC), the survival prognostification of localized pRCC after surgical treatment became inadequate. Sarcopenia was widely evaluated and proved to be a predictive factor for prognosis in RCC patients. Therefore, we comprehensively investigated the survival prediction of the body composition parameters for localized pRCC.
METHODS: Patients pathologically diagnosed with pRCC between February 2012 and February 2022 in our center were enrolled. The body composition parameters, including skeletal muscle index (SMI), subcutaneous adipose tissue (SAT), and perirenal adipose tissue (PRAT), were measured by the images of preoperative computed tomography (CT). The primary outcome was set as progression-free survival (PFS), and the cutoff values of body composition parameters were calculated by using the Youden from receiver operating characteristic curve (ROC) curves. Univariate and multivariate Cox proportional regression analyses were performed to explore independent risk factors for survival prediction. Then, significant factors were used to construct a prognostic nomogram. The performance of the nomogram was evaluated by Harrell's C-index, calibration curves and time-dependent ROC curves.
RESULTS: A total of 105 patients were enrolled for analysis. With a median follow-up time of 30.48 months, 25 (23.81%) patients experienced cancer progression. The percentage of sarcopenia was 74.29%. Univariate Cox analysis identified that gender, PRAT, SAT, skeletal muscle (SM), sarcopenia, surgical technique, and tumor diameter were associated with progression. Further multivariate analysis showed that sarcopenia (hazard ratio [HR] 0.15, 95% confidence interval [CI] 0.03-0.66), SAT (HR 6.36, 95% CI 2.39-16.93), PRAT (HR 4.66, 95% CI 1.77-12.27), tumor diameter (HR 0.35, 95% CI 0.14-0.86), and surgical technique (HR 2.85, 95% CI 1.06-7.64) were independent risk factors for cancer progression. Then, a prognostic nomogram based on independent risk factors was constructed and the C-index for progression prediction was 0.831 (95% CI 0.761-0.901), representing a reasonable discrimination, the calibration curves, and the time-dependent ROC curves verified the good performance of the nomogram.
CONCLUSIONS: A prognostic nomogram, including sarcopenia, SAT, PRAT, tumor diameter, and surgical technique, was constructed to calculate the probability of progression for localized pRCC patients and needs further external validation for clinical use in the future.
Our current understanding of the pathogenesis of CF lung disease stems from data that demonstrate the presence of airway surface liquid (ASL) dehydration in CF. ASL dehydration in CF is caused by defective chloride secretion through the cystic fibrosis transmembrane regulator (CFTR) and increased sodium reabsorption through the epithelial sodium channel (ENaC). ASL dehydration, in turn, interferes with the mucociliary clearance apparatus, causing a breach in a critical line of lung host defense. A number of novel therapeutics are now being developed to address this basic defect of disease, including the use of inhaled hypertonic saline.

Previous work demonstrated that inhaled hypertonic saline (HS) reduces exacerbation frequency and improves lung function in patients with clinically apparent lung disease. A number of issues revolving around the use of HS in CF remain unresolved. First, the typical patients enrolled in previous studies were adults (mean age = 26 yrs) with established lung disease (mean FEV1=78%). Despite our hypothesis that HS should positively affect MCC in preserved/normal airways, a common view of HS is that it benefits CF patients by inducing cough and transiently promoting the clearance of thick CF secretions. It has been questioned, therefore, whether HS will benefit patients who are younger and have mild (or undetectable) lung disease and potentially normal (though unmeasured) rates of MCC. Second, it is unclear whether the substantial beneficial effects of HS in CF were achieved because of a long (\>4 hours) duration of action or in spite of an extremely short (\~45 minutes) duration of action (the traditional view based upon experiments in normal epithelia). This issue is important, as it relates to the development and dosing of hydrator therapies that may have different pharmacodynamic profiles. Certainly, if twice daily dosing of a short acting compound is sufficient to provide significant clinical benefit, it would reduce the challenge of drug discovery for CF and ease the treatment burden imposed upon patients. The study of HS in CF provides us an opportunity to address this issue.

The hypothesis being tested is that HS will rehydrate CF airway secretions, producing a sustained acceleration in MCC in young children with CF, regardless of whether a measurable mucus clearance defect exists at this relatively early stage of disease. We predict a substantial acceleration of MCC will reduce the exacerbation rate in young children with CF. In addition, with the growing number of treatment modalities that are prescribed to patients with CF, adherence to complex and time consuming medical regimens becomes increasingly problematic and important. We therefore, wish to test an improved drug delivery platform for HS- the eFlow (Pari Pharma) vibrating mesh nebulizer, which has the potential to reduce treatment times, improve compliance, and increase treatment efficacy.
INTRODUCTION: The Last Gift study at the University of California San Diego (UCSD), United States enrolls terminally ill people with HIV (PWH) in HIV cure research.
METHODS: From 2017 to 2022, we conducted surveys with Last Gift participants and their next-of-kin/loved ones to evaluate willingness to participate in different types of HIV cure research at the end of life (EOL). We analyzed willingness data descriptively.
RESULTS: We surveyed 17 Last Gift participants and 17 next-of-kin/loved ones. More than half of Last Gift participants ( n  = 10; 58.8%) expressed willingness to participate in studies involving totally new treatments or approaches ('first-in-human' studies), a combination of different approaches, the use of unique antibodies, proteins or molecules, or therapeutic vaccines. Under one-quarter of Last Gift participants ( n  = 4; 23.5%) expressed willingness to participate in research involving interventions that may shorten their life expectancy to benefit medical research. Most Last Gift participants and their next-of-kin/loved ones also expressed high acceptance for various types of donations and biopsies at the EOL (e.g. hair donations and skin, lymph node or gut biopsies).
DISCUSSION: Knowing whether people would be willing to participate in different types of EOL HIV cure research can help inform the design of future innovative studies. As a research community, we have a duty to design studies with adequate safeguards to preserve the public trust in research and honor PWH's important gift to humanity.